Evidence map›Paper›PMID 28293063›Full record

Trial reportDisease markers2017

Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.

Ann Rita Halvorsen, Gunnar Kristensen, Andy Embleton, Cybil Adusei, Maria Pilar Barretina-Ginesta, Philip Beale, Åslaug Helland

Open access · hybridAbstract readRandomized Controlled TrialValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Disease markers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Disease markers · 2019
    Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 4 countries.

Ann Rita HalvorsenDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway.ORCID 0000-0003-1223-7948
Gunnar KristensenDepartment of Gynecologic Oncology, Institute for Cancer Genetics and Informatics and University of Oslo, Oslo, Norway.
Andy EmbletonMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK.
Cybil AduseiDOCs International, Buckinghamshire, UK.
Maria Pilar Barretina-GinestaDepartment of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain; Department of Medical Sciences, Medical School, University of Girona, Girona, Spain.
Philip BealeMedical Oncology, Royal Prince Alfred Hospital and Concord Repatriation General Hospital and Chris O'Brien Lifehouse, Sydney, NSW, Australia.
Åslaug HellandDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway; Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway.ORCID 0000-0002-5520-0275
Oslo University Hospital · NOKES International · GBMRC Clinical Trials Unit at UCL · GBRoyal Prince Alfred Hospital · AUUniversitat de Girona · ESUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer patients are recognized with poor prognosis. This study aimed to identify microRNAs in plasma for predicting response to treatment and outcome. We have investigated microRNAs in plasma from ovarian cancer patients enrolled in a large multicenter study (ICON7), investigating the effect of adding bevacizumab to standard chemotherapy in patients diagnosed with epithelial ovarian cancer. Patients with different histology, grade, and FIGO stages were included (

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabBiomarkers, TumorCarboplatinFemaleHumansMicroRNAsMiddle AgedOvarian NeoplasmsPaclitaxelPrognosisBevacizumabBiomarkers, TumorCarboplatinMicroRNAsPaclitaxel

Identifiers

PMID28293063
PMCPMC5331307
OpenAlexW2588716255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.